Renal transplantation is choice treatment for most patients with end-stage renal disease [
1]. Over the past decade, significant progress has been made in improving graft and patient survival within renal transplantation [
2]. In our center 1 and 3-year renal transplant survival rates were 98.8% and 97.3%, respectively on other hand 1 and 3-year patient’s survival was 96.6% and 93.1% [
1]. Renal transplant survival was thought to be due to combinations of immunosuppressive drugs with different mechanisms of action [
3]. Wide range of immunosuppressive drugs is available to prevent acute rejection after renal transplantation [
4] include cyclosporine, tacrolimus, mycophenolate mofetil, sirolimus, anti-interleukin-2 receptor antibodies, anti-lymphocyte antibodies and everolimus [
5-
8]. However, there was short- and long-term toxicities associated with these immunosuppressive drugs. Such adverse effects can range from the mild through to the severe. Mild adverse events such as nausea, discomfort, appetite loss and severe events include: severe diarrhea, nephrotoxicity, hyperlipidemia, diabetes. These complications decrease patients’ quality of life [
9-
11]. Furthermore, comorbidities linked to immunosuppressant regimens are a major cause of dosage reductions or treatment cessations, which can have a unfavorable effect on efficacy and survival rates [
12,
13]. These adverse effects are not similar in different studies, so the aim of this study was to determine the common complications of medication in renal recipient after renal transplantation.